ERBB2 and neoplasm: A comparison of the IHC findings with the reference results illustrates the risk of underestimation of Her2/neu immunopositive tumor area (<10%): six ratings underestimated the tumor area (<10%) and no SISH would have been carried out leading to denial of medication, although HER2/neu gene amplification was found by SISH.